Equity Overview
Price & Market Data
Price: $20.91
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $325,658,464
Daily Volume: 0
Performance Metrics
1 Week: 8.34%
1 Month: -5.68%
3 Months: 13.46%
6 Months: -6.40%
1 Year: 165.9%
YTD: 1.50%
Company Details
Employees: 131
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.